On July 22, 2014, the *Chinese Journal of Cancer* (*CJC*) received a notification from Thomson Reuters that the publications of our journal starting from 2012 have been accepted for coverage in Science Citation Index Expanded, available at the Web of Science, Core Collection, Biological Abstracts, and Biosis Previews. What this means in practical terms is that *CJC* will receive its first official impact factor (IF) in 2015. This is an important milestone in the history of *CJC*.

As an official journal of the Chinese Anti-Cancer Association (CACA), *CJC* has been a leading cancer journal in China and has published monthly since 2000. To meet the requirement of globalization in cancer research and treatment, *CJC* has undergone a transformation from a Chinese language journal to an English language journal in 2010 and has also become the official journal of the US Chinese Anti-Cancer Association (USCACA). With an international editorial board and English language editors, *CJC* publishes peer-reviewed, open access, and English language scientific articles in the areas of basic, clinical, and translational cancer research that aim to improve human health through understanding cancer, preventing cancer onset, reducing cancer mortality, and improving the quality of life of cancer survivors in the world. *CJC* especially promotes international collaborations and serves as a unique forum for discoveries in cancer types such as nasopharyngeal carcinoma (NPC), liver cancer, gastric cancer, esophageal cancer, which are common cancer types in China and Asia. In addition, *CJC* emphasizes timely cancer issues such as air pollution and cancer, as well as immunotherapy of cancer.

The historical impact of *CJC* is indicated by its indexation in the MedLine (2002), PubMed Center, Directory of Open Access Journals (DOAJ), Scopus, the Western Pacific Region Index Medicus, and CA databases. The impact of *CJC* in the international arena has been steadily increasing after it has become an English language journal in 2010. We have enjoyed strong international support and joined by many internationally renowned cancer investigators. Most importantly, we have received and published many high level manuscripts from established authors from many countries/regions. We are very pleased to see that the historical impact of *CJC* has been markedly augmented in the world. During the last three years, *CJC* papers have been cited by many reputable journals including *Cell*, *Cancer Cell*, *Stem Cells*, *Nature Reviews Cancer*, *Journal of Clinical Investigation*, *Oncogene*, *Cancer Research*, and *Journal of Biological Chemistry*. The estimated impact factor of *CJC* has been growing steadily. *CJC* is supported by the International Impact-promoting Program for Chinese Sci-Tech Journals for 3 consecutive years. *CJC* was entitled Top 100 Outstanding Academic Journals in China for four times from 2010 to 2013 and was recognized as one of the most internationally influential science journals in China in 2013.

We are very excited that *CJC* is now officially recognized by the Thomson Reuters and publications in *CJC* since 2012 will be tracked for citation toward its calculation of impact factor. On this high level, *CJC* will continue to embrace critical thoughts, insightful studies, novel technologies, and meaningful clinical experiences.

We would like to thank the evaluators at the Thomson Reuters for recognizing the value of *CJC*. We want to thank all the editorial board members for their guidance and all the editorial staff for their tireless work. We especially want to thank all our authors for contributing their wonderful work and all the reviewers for providing the top notch professional expertise. This milestone, as important as it is, is a new beginning. Much work is needed to conquer cancer. We need to communicate and collaborate. We need to dream and act. Let *CJC* be the best forum and media for our efforts to fight cancer globally.
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